Henan Lingrui Pharmaceutical Co., Ltd.

SHSE:600285 주식 보고서

시가총액: CN¥12.4b

Henan Lingrui Pharmaceutical 미래 성장

Future 기준 확인 2/6

Henan Lingrui Pharmaceutical (는) 각각 연간 16.1% 및 12.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 26.9% 로 예상됩니다.

주요 정보

16.1%

수익 성장률

15.7%

EPS 성장률

Pharmaceuticals 수익 성장18.7%
매출 성장률12.5%
향후 자기자본 수익률26.9%
애널리스트 커버리지

Low

마지막 업데이트08 Nov 2024

최근 미래 성장 업데이트

Recent updates

An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Oct 28
An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

Oct 13
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

Aug 07
If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Jul 03
A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 07
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

May 02
Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 04
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Feb 29
Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

수익 및 매출 성장 예측

SHSE:600285 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20264,7209598589543
12/31/20254,1948207398183
12/31/20243,7236966226543
9/30/20243,564676611655N/A
6/30/20243,517664682711N/A
3/31/20243,432614756777N/A
12/31/20233,311568792813N/A
9/30/20233,232526847865N/A
6/30/20233,200512904924N/A
3/31/20233,108479805830N/A
12/31/20223,002465808835N/A
9/30/20222,917440654696N/A
6/30/20222,841412574622N/A
3/31/20222,786396637707N/A
12/31/20212,694362769846N/A
9/30/20212,635383663741N/A
6/30/20212,513368688768N/A
3/31/20212,430346460536N/A
12/31/20202,332325379451N/A
9/30/20202,215302367424N/A
6/30/20202,163288336387N/A
3/31/20202,068270386428N/A
12/31/20192,157294391450N/A
9/30/20192,149292442479N/A
6/30/20192,118280447493N/A
3/31/20192,078270413460N/A
12/31/20182,053243384436N/A
9/30/20182,139240319420N/A
6/30/20182,120230N/A356N/A
3/31/20181,990223N/A201N/A
12/31/20171,849217N/A106N/A
9/30/20171,697198N/A18N/A
6/30/20171,608381N/A52N/A
3/31/20171,513364N/A107N/A
12/31/20161,439346N/A63N/A
9/30/20161,315365N/A113N/A
6/30/20161,225152N/A100N/A
3/31/20161,133141N/A110N/A
12/31/20151,085132N/A225N/A
9/30/20151,006119N/A251N/A
6/30/2015936115N/A203N/A
3/31/201590197N/A173N/A
12/31/201482676N/A124N/A
9/30/201480275N/A130N/A
6/30/201475765N/A129N/A
3/31/201471859N/A130N/A
12/31/2013687105N/A127N/A

애널리스트 미래 성장 예측

수입 대 저축률: 600285 의 연간 예상 수익 증가율( 16.1% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 600285 의 연간 수익( 16.1% ) CN 시장( 26.1% 보다 느리게 성장할 것으로 예상됩니다. 26.1% 연간).

고성장 수익: 600285 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 600285 의 수익(연간 12.5% ) CN 시장( 13.8% 보다 느리게 성장할 것으로 예상됩니다. 13.8% 연간).

고성장 수익: 600285 의 수익(연간 12.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 600285 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 26.9 %)

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y